Cologuard test kit. Credit: © Exact Sciences Corporation.

Molecular diagnostics company Exact Sciences and Pfizer have signed a multi-year agreement to co-market the Cologuard test for diagnosing colorectal cancer in the US.

To take place from Q4 2018 to 2021, the agreement will see Pfizer work with Exact Sciences’ sales representatives to bring the Cologuard test to physicians and health systems.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cologuard is one of the only US Food and Drug Administration (FDA) approved and non-invasive stool DNA screening diagnostics for cancer.

“Together we can help reduce the prevalence of colorectal cancer by combining the power of Cologuard and the talented Exact Sciences team with Pfizer’s experience, relationships and resources.”

By promoting the test, Exact Sciences and Pfizer intend to boost colorectal cancer screening rates.

Exact Sciences chairman and CEO Kevin Conroy said: “Pfizer is joining Exact Sciences’ mission of eradicating colorectal cancer by helping detect the disease at its earliest, most treatable stages.

“Together we can help reduce the prevalence of colorectal cancer by combining the power of Cologuard and the talented Exact Sciences team with Pfizer’s experience, relationships and resources.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s sales force, the science of Cologuard and a direct-to-consumer marketing campaign will be combined with Pfizer’s health systems network and marketing expertise.

Pfizer’s internal medicine North America regional president Nick Lagunowich said: “By joining forces with Exact Sciences to bring this non-invasive colorectal cancer screening option to more providers and their patients, we hope to substantially increase the early detection of colorectal cancer.”

Exact Sciences will continue to carry out all manufacturing and laboratory operations of the test. Pfizer will evenly share gross profits and marketing costs above an agreed baseline.